Search

As a result of this project, our facility instituted a new protocol using a reduced dose of alteplase to restore patency to non-HD CVADs” Plohal and Schiller (2017).

Abstract:

Central line-associated bloodstream infections (CLABSIs) are preventable through vigilant and thorough care.1 When CLABSIs occurred at a facility in Southwest Arizona, the root cause analysis discovered that declotting agents, such as alteplase, were not given routinely when nonhemodialysis (non-HD) central vascular access devices (CVADs) lacked blood return. A PICO question was developed that guided the review of literature and central line care standards of practice: In the adult patients with non-HD central lines, what medications are currently recommended to restore patency? As a result of this project, our facility instituted a new protocol using a reduced dose of alteplase to restore patency to non-HD CVADs.

[ctt link=”u6dRS” template=”1″]ReTweet if useful… What is the most effective Alteplase dose to restore CVAD potency? https://ctt.ec/u6dRS+ @ivteam #ivteam[/ctt]

Reference:

Plohal, A. and Schiller, K. (2017) Efficacy of Reducing Alteplase Dose to Restore Patency in Nonhemodialysis Central Vascular Access Devices. Journal of Infusion Nursing. 40(2), p.112–115.

doi: 10.1097/NAN.0000000000000209

Thank you to our partners for supporting IVTEAM
[slideshow_deploy id=’23788’]